Future studies will involve assembling tissue collections of early stage melanomas to verify whether RhoJ is an ideal therapeutic target for early stage disease and determine whether RhoJ inhibition blocks both tumor growth and metastasis. This evidence concerns the gene RHOJ and neoplasm.